Nov 28, 2023 / 08:50PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
(technical difficulty)
for being here. Pleasure to have management team from Eli Lilly. There's a ton to go through. But Dan, I'll turn it over to you on what's on top of your mind, and we'll jump right into it.
Daniel M. Skovronsky - Eli Lilly and Company - EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Yes. No. Thanks for hosting us here. It's been a great meeting so far, and nice to have this opportunity to talk at a fireside. I guess probably most people are excited about Lilly because of what we're doing in obesity and Alzheimer's disease. But just a reminder that we have a great business in immunology with a couple of new products being planned to launch.
We're also doing great things in oncology with Verzenio as a huge product and Jaypirca, which is in the early stages of launching across indications. So really a very diversified pharmaceutical company even though I
Eli Lilly and Co at Evercore ISI HealthCONx Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers